



Immune thrombocytopenic purpura (ITP) is an acquired 
hematological disorder in which antiplatelet antibodies 
cause accelerated destruction of platelets by the cells of the 
mononuclear phagocytic system.[1] The disorder affects both 
children and adults. Adult‑type ITP is insidious in onset and 
often pursue a protracted course.[1] The incidence of ITP in 
adults is estimated to be between 1.6 and 3.9 per 100,000 per 
year.[1] As with most autoimmune disorders, adult‑type ITP 
commonly occurs in females: The prevalence in males and 
females between the ages of 18 and 64 years is 16.6 and 
27.2 per 100,000, respectively.[1] The prevalence increases 
significantly after the age of 65 years. Chronic infections, 
bacterial and viral, vasculitides, and some drugs, are implicated 
in the etiopathogenesis of ITP.[1‑3] Thrombocytopenia following 
insertions of hormonal contraceptive implants was reported by 
the United States Food and Drug Administration in 6 women 
between 1991 and 1993.[4]
Studies in Nigeria and other parts of the world have shown 
that bleeding disorder constitutes one of the most comon 
reasons for discontinuation of contraceptive implants 
with documented evidence of thrombocytopenia among 
the study population.[5,6] However, the mechanism of 
thrombocytopenia has not been explained in these studies. 
The thrombocytopenia may be as a result of immune‑mediated 
destruction by antiplatelet antibodies. As women are becoming 
empowered to make an informed decision about family size, 
levonorgestrel‑containing   contraceptive implants have 
become the preferred method of contraception.
Here, we report the occurrence of ITP in association with a 
hormonal contraceptive implant in a newly established tertiary 
health facility in the North‑East geopolitical zone of Nigeria.
case report
Patient U. F. A, a  39‑year‑old  P10
+0 7 alive presented to 
the Yobe State University Teaching Hospital, Damaturu, 
Immune thrombocytopenic purpura (ITP) is an acquired disorder of platelets that clinically manifests with mucocutaneous bleeding. There are 
several causes of ITP, but its association with hormonal contraceptive implants has not been widely reported. A 39‑year‑old Para 10+0 7 alive 
presented to the Yobe State University Teaching Hospital with complaints of nasal bleeding, gum bleeding, purpura, and menorrhagia, which 
were noticed a month after insertion of a  Levonorgestrel – containing  hormonal contraceptive implant, at a Primary Healthcare facility. Complete 
blood count, peripheral blood film, and bone marrow aspiration cytology led to the diagnosis of ITP. Epistaxis was managed conservatively. 
The patient was placed on prednisolone with a noticeable increase in platelet count and remarkable improvement in the clinical state. ITP is a 
complication of the hormonal contraceptive implant. Clinicians should be aware of the possible association of contraceptive implants and ITP.
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Yobe State, North-Eastern Nigeria, with a 4-month history 
of epistaxis, gum bleeding, purpura and bleeding per 
vagina. Symptoms commenced 4 weeks after the insertion 
of  levonorgestrel–containing hormonal contraceptive implant, 
at a Primary Healthcare facility. Epistaxis was said to be 
spontaneous, recurrent, and bilateral. She noticed gum bleeding 
on brushing her teeth. Bleeding per vagina presented as spots 
with no significant clots. No previous history of menstrual 
irregularities or use of contraceptives and no history of 
intrapartum or postpartum hemorrhage. There was no fever, 
weight loss, night sweats, bone pain, abdominal swelling, 
or jaundice. No history of bleeding from orifices before the 
use of the contraceptive implant. She was diagnosed with 
hypertension during her last pregnancy. She was not a known 
diabetic. She had five units of blood transfused before the 
presentation.
On examination, she was acutely-ill, not dehydrated, 
moderately pale, anicteric with a conjunctival hemorrhage 
in the right eye [Figure 1]. No significant peripheral 
lymphadenopathy. Purpuras were present on the antecubital 
fossae. No pedal edema. Her weight and height were 46.9 kg 
and 1.55 m, respectively.
The cardiovascular system was remarkable for tachycardia (pulse 
rate of 108 bpm), and hypertension (blood pressure [BP] 
217/135 mmHg). There was mucosal ulceration in the little’s 
area on the right nostril and hematoma in the gums [Figure 2]. 
The abdominal examination was unremarkable. She had 
normal external female genitalia, with the vulva moderately 
stained with blood.
Complete blood count (CBC) was as follows: Packed cell volume 
32%, total white blood cell count was 4.0 × 109 (Neutrophils 
57%, Lymphocytes 34%, Eosinophils 2.0%, Monocytes 7.0%). 
The platelet count was 23.0 × 109/L (Local reference range is 
100–400 × 109/L). Peripheral blood film examination showed 
microcytic hypochromic red cells with target and pencil cells. 
There were no fragmented red cells. Platelets were markedly 
reduced with few giant forms on film.
Bone marrow aspiration (BMA) cytology showed a 
normocellular marrow for age with trilineage haematopoiesis 
but with reduced megakaryocytes. Erythropoiesis was 
predominantly micronormoblastic. The myeloid series was 
unremarkable [Figure 3]. The direct antiglobulin test (DAT) 
was negative. Fasting blood glucose was 4.3 mmol/L. 
Electrolytes, urea, and creatinine were within reference limits. 
Viral screening for HIV, Hepatitis B, and C was negative.
We made a diagnosis of ITP secondary to hormonal 
contraceptive implant and hypertensive emergency. We 
controlled the elevated BP with intravenous (IV) Hydralazine 
and Tablets Alpha-Methyldopa and placed her on tablets 
prednisolone at a dose of 1 mg/Kg body weight (15 mg tid) and 
hematinics. Anterior nasal packing was done and also placed 
on Tabs Dicynone 500 mg tid for 10 days. We counselled 
her on the removal of the implant and the use of alternative 
forms of contraceptive. On the 3rd day of prednisolone, the 
platelet count increased to 67.0 × 109/L, and bleeding ceased. 
On the 4th day of admission, a two-rod contraceptive implant 
was removed under aseptic condition. On the 6th day, platelet 
count increased to 87.0 × 109/L, and she was discharged 
home on drugs.
On her first follow‑up visit, the platelet count increased to 
109 × 109/L. Two weeks later, she came back with facial 
swelling and a Platelet count of 110 × 109/L. We explained to 
her the reason why she had the facial swelling (moon face). 
We reduced the dose of prednisolone to 10 mg tid. She was, 
however, lost to follow-up for 3 months. The patient, however, 
returned with mucocutaneous bleeding of 1-week duration. She 
stopped taking drugs for the past 3 months that she defaulted 
follow‑up citing financial constraints as the main reason. 
Her platelet count dropped to 20.0 × 109/L. Prednisolone 
was recommenced at a dose of 10 mg bid. At follow-up, the 
platelet count increased to 404.0 × 109/L. We tapered the dose 
of prednisolone to 5 mg bid, and the platelet count remained 
at 173.0 × 109/L.
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Figure 1: Conjunctival haemorrhage in the patient’s right eye
Figure 2:  Haematoma in the patient’s gum
Figure 3: Bone marrow aspiration cytology film (×100), showing a 
megakaryocyte
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dIscussIon
The occurrence of ITP after insertion of hormonal contraceptive 
implant is uncommon, the diagnosis of ITP in our patient 
confirmed and added to these rare complications.
ITP is an acquired hematological disorder associated with 
antibody-mediated shortening of platelets’ lifespan. Platelets 
have a normal lifespan of about 7–10 days in the circulation 
but, this is shortened to a few hours in ITP.[1,2] The marrow 
response in patients with ITP cannot keep pace with the 
rate of peripheral destruction, leading to thrombocytopenia. 
Implicated autoantibodies are predominantly of the 
immunoglobulin G class; the remainders are immunoglobulin 
M and immunoglobulin A.[2] In most cases, the antiplatelet 
autoantibodies target the glycoprotein IIa/IIIb on the platelets 
membrane, leading to the destruction of the antibody-coated 
platelets in the spleen.[2] Cellular immunity and complements 
have also been implicated in the pathogenesis of ITP.[2] Available 
knowledge also attributed thrombocytopenia to platelet 
underproduction as a result of immune-mediated destruction of 
megakaryocytes.[1] Consistent with ITP, our patient presented 
with marked thrombocytopenia with mucocutaneous bleeding. 
A review of the BMA cytology   of our patient revealed that 
although megakaryocytes were present, they were reduced in 
number. This finding further confirmed earlier observations of 
immune-mediated suppression of megakaryopoiesis in some 
cases of ITP.
The contraceptive implant  used by our patient, contains the 
synthetic hormone, levonorgestrel. It is a two-rod implant, and 
each rod contains 75 mg of the progestin, levonorgestrel.[7] It 
works mostly by suppressing ovulation, thickening of cervical 
mucus, slowing ovum movement through the fallopian tubes, 
and alteration of the endometrium.[7] Injectable contraceptives 
such as deport medroxyprogesterone acetate have also 
been associated with ITP.[8] When we consider the onset of 
bleeding, it seemed likely that the  hormonal contraceptive 
implant  used by our patient, was causally associated with the 
thrombocytopenia.
The diagnosis of ITP is based on the exclusion of other causes 
of thrombocytopenia.[1,2] Clinically, ITP may present with 
mucocutaneous bleeding, a reflection of perturbed primary 
hemostasis. Laboratory findings in support of ITP on CBC 
include thrombocytopenia without anemia and leucopenia. 
The diagnosis of ITP in our patient was based on the finding 
of thrombocytopenia on full blood count and the presence 
of megakaryocytes without morphological evidence of 
dysplasia on BMA  cytology. The diagnosis of ITP was further 
strengthened clinically by the absence of splenomegaly, and 
therapeutically, by the observed increase in platelet count 
with the commencement of a corticosteroid. The microcytic 
hypochromic anemia seen in our patient could be as a result 
of iron deficiency from the combination of chronic blood loss 
for over 4 months, increased iron demands of lactation, and 
the background poor socioeconomic status. Evans Syndrome, 
a close differential of ITP, was ruled out by negative DAT and 
the absence of schistocytes on peripheral blood smear. The role 
of BMA in the diagnosis of ITP has been debated.[9] However, 
BMA can help to rule out other causes of thrombocytopenia. 
The hallmark of the diagnosis of ITP is the demonstration 
of antiplatelet antibodies. However, routine tests for the 
implicating anti-platelets antibody in clinical practice are not 
advocated because of low sensitivity.[1]
The American Society of Hematology Guidelines 2011 
recommended that treatment be administered for patients 
with platelets count <30 × 109/L.[10] Our patient presented 
with a platelet count of 23.0 × 109/L with mucocutaneous 
bleeding, therefore justifying the commencement of treatment. 
Corticosteroids, with or without IV immunoglobulin, are the 
first‑line treatment for newly diagnosed ITP.[1,2] Prednisolone 
monotherapy at a dose of 1 mg/kg was used in our patient 
with significant improvement in platelet count and cessation 
of bleeding.
conclusIon
With the increasing awareness of the need for child-spacing, 
the hormonal contraceptive implants have become a preferred 
choice of contraceptives in Nigeria. This report, therefore, 
seeks to create awareness among clinicians about the possible 
causal association between hormonal contraceptives and 
immune-mediated thrombocytopenia. Clinicians may need to 
serially or periodically monitor platelets count of their clients 
on hormonal contraceptives.
Limitations
An assay that can detect and quantify antiplatelet antibodies 
is the gold standard for the diagnosis of ITP. However, such 
an assay is unavailable in our center.
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